Examination of the antioxidative and antidiabetic effect of pomiferin in alloxan-induced diabetes mellitus in an experiment (a pilot study)

Overview

The antioxidative and antidiabetic effect of pomiferin was monitored under the experimental conditions of alloxan-induced diabetes mellitus. The animals were divided by random selection into 2 groups (n=7). The treated group was administered pomiferin in peroral doses of 10 mg/kg in Avicel, the placebo group was given only a solution of Avicel, and the last group was intact. Selected laboratory parameters (glucose, urea, cholesterol, antioxidative enzymes, total antioxidative capacity, malondialdehyde in serum; diuresis, total glucose and protein losses through urine) were determined. Kidney tissue and pancreas samples were taken for histopathological analysis. The findings included a statistically significant decrease (p≤0.01) in blood glucose level, a significant increase (p≤0.01) in glutathione peroxidase, total antioxidative capacity (p≤0.05) and a significant decrease (p≤0.01) in malondialdehyde level in the treated group compared to the placebo group. A highly significant decrease (p≤0.01) in diuresis, glucose and protein losses through urine were identified in the treated group compared to the placebo group. The superoxide dismutase catalytic activity, urea and cholesterol levels involved nonsignificant changes. The results of biochemical examination show a protective antioxidative and antidiabetic effect of pomiferin. The results of histopathological examination correlate with them only partially.

Key words:
pomiferin – diabetes mellitus – antioxidant